MaaT Pharma, a prominent biotech company specializing in Microbiome Ecosystem Therapies (MET) for cancer patients, and Skyepharma, a French independent CDMO engaged in bioproduction and complex drug development and manufacturing, have achieved a significant milestone by completing the largest microbiome therapy facility in Europe. This facility marks a significant step forward in advancing the field of microbiome therapies and enhancing bioproduction capabilities in France and Europe.
MaaT Pharma, renowned for its expertise in microbiome research for oncology, is one of the few companies involved in the entire process of microbiome therapy development, from innovative bioprocesses to GMP-compliant manufacturing for drug candidates derived from donors or co-cultured sources.
The completion of this state-of-the-art facility brings positive economic impacts to the region and the nation as a whole. In the coming years, the partnership between MaaT Pharma and Skyepharma is expected to generate around a dozen specialized jobs in the industry, contributing to the growth of the microbiome sector in France. These jobs will require advanced manufacturing techniques and adherence to complex procedures to meet the demands of microbiome therapies.
The quality qualification of the facility is currently underway, in accordance with Good Manufacturing Practice (GMP) guidelines. The first production campaign is scheduled to commence by the end of the third quarter of 2023.
The collaboration between MaaT Pharma and Skyepharma not only strengthens their positions as pioneers in the field of microbiome therapy but also showcases their commitment to advancing the ecosystem of bioproduction capabilities in Europe. As the largest cGMP facility in Europe dedicated to microbiome therapies, it sets a benchmark for future developments in this field.
In summary, the completion of Europe’s largest microbiome therapy facility by MaaT Pharma and Skyepharma signifies a significant milestone in the advancement of microbiome therapies. The collaboration between these industry leaders not only contributes to the growth of the microbiome sector in France but also enhances bioproduction capabilities in Europe. With the facility’s completion, both companies are well-positioned to continue their groundbreaking work in the development of innovative therapies that improve survival outcomes for cancer patients.
